A clinical trial from Johns Hopkins University produced results showing that participants who took a single dose of psilocybin, the active compound in magic mushrooms, had more than six times greater odds of being cigarette-free at the six-month mark compared to those using nicotine patches. “I was surprised by the sheer magnitude of the effect,” said Matthew Johnson, the study’s lead author and professor of psychiatry at Johns Hopkins.
The study enrolled 82 current smokers, randomly divided into two groups. Both underwent 13 weeks of cognitive behavioral therapy for smoking cessation. One group used nicotine patches; the other took a relatively high dose of pure psilocybin in a single guided session. Participants in the psilocybin group lay in a room wearing eye shades and listening to soft music, with facilitators present to keep them comfortable.
At six months, 17 people in the psilocybin group had stayed off cigarettes, compared to only four in the nicotine patch group. The study included no placebo control. Johnson acknowledged the findings need to be replicated in a larger, more diverse study before drawing firm conclusions. The National Institutes of Health has already funded him for a larger ongoing trial that includes a placebo arm.
Different Approach
Seven medications are currently approved for smoking cessation in the United States, most working by targeting nicotine receptors directly. Psilocybin takes a completely different route. With the best available medications and counseling combined, long-term quit rates hover between 20 and 30 percent per attempt. “How do we help those folks?” asked Megan Piper, director of the UW Center for Tobacco Research and Intervention.
Johnson described what appears to be happening at a behavioral level: “When people are on a compound like psilocybin, the brain is communicating with itself in very different ways.” What follows seems to be a genuine shift in perspective and a new sense of agency, with participants stepping outside familiar patterns. Dr. Brian Barnett of the Cleveland Clinic suspected the intensive therapeutic structure around the psilocybin session was also central to the outcome. “It’s not the drug by itself here. It’s really harnessing the neuroplastic and learning effects that happen after the exposure.”
Broader Research
This study builds on a smaller pilot Johnson ran more than a decade ago. Research into psilocybin for alcohol dependence has also shown early promise, and ibogaine is drawing attention for opioid use disorder. Smoking remains the leading cause of preventable death in the United States, and it has been 20 years since a new medication to help people quit was developed.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.optimistdaily.com/2026/03/a-single-dose-of-psilocybin-gave-smokers-six-times-better-odds-of-quitting-than-the-patch/